🔗 Share this article

While the US proceeds with historic changes to its vaccine schedules, one figure has emerged unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by expressing skepticism about COVID-19 shots throughout the pandemic and has concentrated on potential fatalities after COVID-19 immunization in her short time at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Program

Agency leaders had intended to announce radical changes to the childhood vaccination calendar recently, bringing the US with Denmark’s vaccine program, according to reports – a substantial departure that would place the US at odds with a large portion of the international standard with insufficient data for benefit. The announcement has been delayed until the next year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to address the audience at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this year.

A Shift at the FDA

The acting appointment may indicate a closer partnership between the drug and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon reevaluating already-approved immunizations at the FDA.

Høeg has repeatedly called for halting certain childhood vaccine recommendations in the US so as to align more in line with Denmark, a society with universal health coverage and a citizenry about the size of the state of Wisconsin.

So far public appearances, she has kept her attention on immunizations – usually the responsibility of Dr. Prasad, director of the FDA’s CBER – rather than medication approval.

Concerns Over Background

Dr. Høeg has no obvious background in medication creation, approval processes or administrative roles, which has been typical for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and CBER since March.

“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in running a major agency. She has no expertise in industry regulation.”

Former heads of CBER would “understand regulatory frameworks and the research of drug development”, commented Dr. Janet Woodcock. “Frankly, she lacks the kind of background that prior appointees who ran CBER have had.”

The drug center has an immense portfolio at the agency, she emphasized.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and so forth, and every single one have to be looked after,” she explained. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

There is also, a significant administrative element to the job, which oversees in excess of 5,000 staff members. “It is a enormous administrative position, if you execute it properly,” Woodcock said.

Official Statement and Disputed Programs

When asked about inquiries about Høeg’s credentials and whether this appointment indicates greater collaboration among agency officials on vaccines, a press secretary responded that the “concerns rely on incorrect premises”.

“This background matches the functions of her role,” the spokesperson said, pointing to the time Høeg spent counseling the agency head on “medication safety and approval science, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the agency head's new expedited review system, a disputed one-day therapy clearance system that allegedly concerned her predecessors. “How are these therapies being selected for this expedited pathway? Who makes the choices?” Howard asked. “There is a lot of confidentiality going on at the agency right now.”

In general, he stated, “the FDA looks to be trending towards laxer regulations of pharmaceuticals, aside from shots.”

Established History on Vaccines

With vaccines, Dr. Høeg has a more established, if troubling, track record, critics said. She published a research paper using non-validated public submissions to assess the frequency of heart inflammation after Covid immunization. She counseled the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccinations are pose a greater threat than they are.

Included in her “desired changes” for the new government encompassed revising guidelines for recently developed shots and ending “optional” immunizations, she stated after the election on a online show. At the agency, Dr. Høeg has reportedly proposed excluding adolescent males from getting COVID-19 vaccinations.

“She’s an thorough true believer who commences with her beliefs and tailors the evidence to accommodate the science in a extremely disingenuous, untruthful manner,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow skeptics, {like|